Archive | April, 2023

The Innovator’s Pitch Challenge – Applications Due Tomorrow!

20 Apr

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

The Innovator’s Pitch Challenge (IPC) is a highlight of the Redefining Early Stage Investment (RESI) conferences! Innovative startups in life science and healthcare showcase their technology by pitching to investors in a live Q&A format, providing feedback, practice, and, sometimes, valuable connections that lead to deals. All finalists are divided into separate IPC sessions based on similar sectors and technologies. This allows relevant investors and industry professionals with field expertise to provide targeted questions and feedback. IPC participation also includes a space to exhibit a posterboard highlighting their product or technology in a large exhibit hall for the full day of the conference. With the live Q&A session and poster exhibit, companies are able to boost their exposure and increase their chances of networking with relevant investors and strategic partners.

2022_0921_RESIBoston_007-800x534Pitch & Investor Q&A

2022_0921_RESIBoston_001s-800x534IPC Poster

Over 30 companies have been confirmed to pitch at RESI Boston on June 5 and there is one day left to apply until the deadline of tomorrow, Friday, April 21.

If you are involved with an early-stage life science company, actively fundraising, and want to boost your exposure, gain valuable feedback from investors and industry experts, and secure meetings with investors who have a genuine interest in your technology, apply today!

Below is a list of companies who have been accepted as finalists for RESI Boston, June 5-7. In-person conference attendees will be provided with “RESI Cash” that can be used to vote for their favorite pitch.

Featured Pitch Companies

ipc-end-bANNER -2RESI-Boston-2023-June-1100px

How Tech Hubs Can Get Involved at RESI Boston, June 5-7

20 Apr

By Erika Wu, Business Development Manager, Global Tech Hubs, LSN

RESI Boston, June 5-7 will be in-person on June 5, followed by two days of virtual partnering on June 6-7. If you are part of a tech hub, Life Science Nation (LSN)’s Redefining Early Stage Investment (RESI) conference series is a great place for companies in the earliest stages of the life science industry to connect with potential investors. An integral part of RESI is the global tech hub ecosystem of accelerators, incubators, non-profits, universities, tech transfer offices, and regional organizations.

Through RESI, tech hub affiliated startups gain access to resources beyond partnering with investors and strategic partners. Resources such as the LSN Investor Database, Innovator’s Pitch Challenge (IPC), free workshops, and Entrepreneurial Courses. These tools help develop compelling marketing materials, build meaningful relationships with investors and secure necessary early-stage funding.

At RESI Boston, June 5-7, tech hub organizations and their startups can utilize:

  • Super Early Bird Registration Rates for full conference or virtual only registrations (startup must be from LSN’s tech hub partners)
  • Complimentary tech hub staff registration
  • 50% off sponsorship opportunities
  • Free second attendee registration for Innovator’s Pitch Challenge (IPC) participants

Life Science Nation will host a free webinar, How Tech Hubs Can Get Involved at RESI Boston, on Wednesday, May 3rd at 12:00PM ET. Register here.

This free webinar is designed for tech hub organizations ranging from accelerators, incubators, non-profits, universities, tech transfer offices, regional organizations, and more who set up their early-stage life science startup constituents for success with their entrepreneurship and fundraising journey. It will showcase the tools and resources that LSN makes available for Tech Hubs to help their startups who’ve raised less than $2M USD in capital expand their outreach from Regional to Global, build a target list of investors, get involved with the RESI conference series, and more. This webinar will be hosted by Erika Wu, BD Manager of Global Tech Hubs.

FREE_TECH-HUB-WEBINAR_Banner

For more information, please contact Erika Wu, Business Development Manager, Global Tech Hubs of LSN.

RESI-Boston-2023-June-1100px

Connect with 300+ Innovative Life Science Startups at RESI Boston Conference

20 Apr

By Candice He, Vice President of Business Development, Global Investment Strategist, LSN

Are you representing a service provider, big pharma/medtech, or investor looking to connect with innovative life science startups? Don’t miss the upcoming RESI Boston Conference from June 5-7! With over 300 startups from the therapeutics, medical devices, diagnostics, and digital health/healthcare IT sectors expected to attend, this event provides the perfect opportunity to find your next strategic partner or investment opportunity.

As a registered attendee, you’ll have access to a range of networking opportunities, including 1-1 Partnering Meetings. This efficient system allows you to schedule meetings with startups based on a fit of sector, indication and phase of development.

You can also participate in the Innovator’s Pitch Challenge, where you can hear from some of the most promising startups in the industry as they pitch their ideas to seek licensing opportunities and early-stage funding. This is a great way to get a quick overview of what’s new and exciting in the space.

In addition to these opportunities, RESI Boston also offers sponsored workshops and exhibition spaces, where you can showcase your existing programs, products and services, gaining extra exposure from peers and experts.

Check out RESI Sponsorship Brochure

Don’t miss out on this incredible opportunity to connect with cutting-edge startups and gain valuable industry insights. Register for RESI Boston today and take the first step towards building the future of the life sciences industry.

Check out the RESI Boston June 2023 Featured Startups* below:

*As of April 18, 2023

cs4202023

RESI-Boston-2023-June-1100px

Hot Investor Mandate: Investment Arm of Non-Profit Organization Focuses on Life Science Technologies Targeting Blood Diseases, Infectious Diseases, and More

20 Apr

A venture arm of a non-profit organization with offices in the US closed an initial fund of $50M USD dedicated to early-stage life science ventures from Series A to C. The initial size of investment ranges from $250k-2M and the firm aims to invest in 10 companies in the upcoming year. The firm prefers to invest in US-based companies but is open to global opportunities.

The firm is niched on four key areas of focus: benign hematology, transfusion medicine, cell therapy, and infectious diseases. The firm will consider therapeutics, diagnostics, and medical devices. The firm will consider therapeutics of all modalities from Pre-Clinical to Phase II. Within diagnostics, the firm is opportunistic and looks at technologies in clinical phases or on the market (must include proof of concept). Within medical devices, the firm is open to all technologies, but is more interested in cell therapy-enabling technologies in clinical phases or on the market (must include proof of concept). Focused on the need for blood-related and cellular technologies, the firm is interested in making not only a financial, but humanitarian investments that also tie back to the parent company.

The firm highly values working with a management team that is 100% committed to the project. The firm prefers that the team has an even distribution of members with scientific and commercial expertise. The firm is a strategic co-investor and seeks to work with the respective knowledge experts on the team.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Corporate VC Invests in Early-Stage Life Science Companies, With Strongest Interests in Therapeutics Across All Modalities

20 Apr

A corporate venture arm of a global company has offices in US and Europe. This fund makes equity investments in early stage companies several industries, including healthcare and life sciences. The firm typically leads or co-leads rounds as a member of a syndicate of investors, and is actively seeking new investment opportunities across all funds.

Within life sciences, the firm is looking for early stage companies working primarily within therapeutics, but is open to other sectors and has made investments in medical devices, diagnostics, and digital health. The firm seeks to invest in areas of strategic interest to its parent company including Immunology (Autoimmune), Oncology, Immuno-oncology, and Fertility. The firm generally looks for companies with novel first-in-class preclinical stage assets as well as novel platform technologies. In addition, the firm is seeking innovation for process, research and/or applied solutions.

The firm is looking for privately held companies with experienced management teams able to take innovative solutions into commercially viable products. The firm looks to take an active role following investing taking a board seat. The firm is able to invest globally.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based Family Office Invests Globally, With Broad Interests in Promising Life Science Technologies

20 Apr

A family office based in the US represents approximately 2100 doctors, HNW investors, and angel investors. The firm invests in, but is not limited to, biotechnology, medical devices, and pharmaceuticals. Typical allocation size is $100k-250k per investor, participating in both leading investments and co-investing. The firm invests in companies worldwide, with no specific geographic preferences. Recently, the firm had 3 exits in the life science sector.

The firm is opportunistic in terms of sectors of interest. The firm invests in biotechnology, medical devices, pharmaceuticals, and anything relevant to life sciences that seems to be a good opportunity for the firm. The firm is open to all financial rounds and all stages of development as well as orphan diseases and all indications.

The firm does not have any management team requirements, although depending on the case, taking a board seat may be requested.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: China-Based Company Seeks Global Investment and Strategic Partnering Opportunities With Innovative IVD Products

20 Apr

A large high-tech biological company focuses on rapid diagnostics in China – the company has gone public a few years ago. Apart from their headquarters, the firm has an international presence in Europe, Asia, and North America. The firm is open to different forms of partnership including license-in, joint venture, buyout, and equity investment for early-stage companies.

The firm has a strong interest in IVD sectors for innovative products addressing the unmet needs of healthcare providers.

The firm is open to global opportunities while preferring companies with a Chinese angle.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.